AXIOGENTRUST · HIPAA & BUSINESS ASSOCIATES
Why AxiogenResearch
Talk to our team↗
Platform
  • Overview
    One predictive layer underneath every department — start here.
  • Data Assets
    72,224 U.S. practice identities · social-media corpus as of Mar 2026.
  • API & Infrastructure
    REST + GraphQL · SDKs · sub-second queries · production-grade JSON.
  • Integrations & Security
    SAML SSO · SCIM · native CRM, BI, and MLR write-back.
One ontology · every departmentSee platform overview →
By Department
  • Commercial & Field Operations
    Territory managers, marketers, and PDMs — predictive conquesting.
  • Medical & Scientific Affairs
    KOL + DOL mapping, innovation signals, trial site selection, and proactive PV.
  • Operations, Quality & Regulatory
    Off-label surveillance, AE triage, and channel integrity — in real time.
  • Corporate Functions
    TAM / SAM modeling, M&A screening, and executive dashboards.
Product
  • Sales Ops
    Prospecting intelligence for aesthetics pharma commercial teams.
One ontology · every departmentCompare all four departments →
Platform
  • Overview→
    One predictive layer underneath every department — start here.
  • Data Assets→
    72,224 U.S. practice identities · social-media corpus as of Mar 2026.
  • API & Infrastructure→
    REST + GraphQL · SDKs · sub-second queries · production-grade JSON.
  • Integrations & Security→
    SAML SSO · SCIM · native CRM, BI, and MLR write-back.
Solutions · By Department
  • Commercial & Field Operations→
    Territory managers, marketers, and PDMs — predictive conquesting.
  • Medical & Scientific Affairs→
    KOL + DOL mapping, innovation signals, trial site selection, and proactive PV.
  • Operations, Quality & Regulatory→
    Off-label surveillance, AE triage, and channel integrity — in real time.
  • Corporate Functions→
    TAM / SAM modeling, M&A screening, and executive dashboards.
Product
  • Sales Ops→
    Prospecting intelligence for aesthetics pharma commercial teams.
More
  • Why Axiogen→
    The unified ontology underneath the whole platform.
  • Research→
    Frontier insights from the Axiogen lab — papers and signals.
  • Manifesto→
    Why we exist — a letter from the founder.
Log inTalk to our team↗
Trust & Legal
  • Privacy Policy
  • Terms of Service
  • Data Processing Addendum
  • HIPAA & Business Associates
  • Security & Trust
  • Contact
DRAFT · UNDER LEGAL REVIEW

Questions about these documents? Email enterprise@axiogen.ai.

HIPAA & Business Associate Information

Effective Date: [Effective Date]
Last Updated: [Last Updated Date]

Draft notice. This document is provided for informational purposes and as a high-quality starting draft. It does not constitute legal advice. Axiogen's actual policies and agreements must be reviewed, customized, and approved by qualified legal counsel licensed in the relevant jurisdictions before publication or use.


1. Our HIPAA posture in one paragraph

Axiogen AI ("Axiogen") builds commercial and market intelligence for pharmaceutical and medical-device companies in medical aesthetics. Our core dataset describes practices and practitioners in their professional capacity — not patients — and is assembled from public and commercially licensed sources. That data is not Protected Health Information ("PHI") under the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations ("HIPAA"). Axiogen is not a Covered Entity. We become a Business Associate only when a Covered Entity (or another Business Associate) chooses to upload PHI to the Platform or to instruct us to process it, and in that case we do so under a signed Business Associate Agreement ("BAA"). Our security program is designed to align with the HIPAA Security Rule's administrative, physical, and technical safeguard standards, and we support customers' HIPAA obligations with the controls described below. There is no such thing as HIPAA "certification," and we do not claim one.


2. What the Axiogen dataset is — and is not

The Axiogen dataset containsThe Axiogen dataset is not designed to contain
Professional information about clinicians, injectors, and practice staff: credentials, licensure, NPI, practice affiliations, professional contact detailsPatient names, records, or identifiers
Practice-level information: locations, services and products offered, devices, firmographics, public reviews about the practiceTreatment, diagnosis, or health-status information about any patient
Publicly posted professional and practice social-media content and engagement metricsHealth information about the professionals themselves
Public regulatory and transparency records (e.g., FDA, USPTO, CMS Open Payments)Insurance, claims, or billing information
Derived analytics: segments, scores, influence tiers, relationship graphs, next-best-action recommendationsElectronic health records or any clinical system integration

Where a public source incidentally contains patient-related content (for example, a practice's public post), Axiogen does not extract, index, or profile the individuals concerned. [CONFIRM WITH ENGINEERING and keep consistent with the Privacy Policy, Section 3.3.]

Because the dataset concerns professionals and businesses rather than patients, our customers can use the Platform for territory planning, KOL identification, credential validation, and outreach planning without creating a Business Associate relationship with Axiogen.


3. When Axiogen acts as a Business Associate

A Business Associate relationship arises only when a customer that is a Covered Entity or Business Associate under HIPAA elects to have Axiogen create, receive, maintain, or transmit PHI on its behalf. Examples could include a customer uploading patient-support-program data, adverse-event follow-up records, or other Customer Content that identifies patients.

In that situation:

  1. A BAA must be signed before any PHI is uploaded. Our Terms of Service and Data Processing Addendum prohibit uploading PHI without one.
  2. The BAA governs. It sets out the permitted uses and disclosures of PHI, our safeguard obligations, breach reporting, subcontractor flow-down, individual-rights support, and return or destruction of PHI at the end of the engagement.
  3. PHI is processed only as instructed. We use and disclose PHI only as permitted by the BAA and as required by law, and never for Axiogen's own purposes, for marketing, or to enrich the shared Axiogen dataset.
  4. Minimum necessary. Customers are asked to limit uploaded PHI to the minimum necessary for the purpose, and Platform features should be scoped accordingly.

Most pharmaceutical manufacturers are not themselves Covered Entities for their commercial operations, and most Axiogen use cases do not involve PHI. If you are unsure whether your intended use involves PHI, contact [Legal Contact Email] before uploading data, and consult your own privacy counsel.


4. Our standard Business Associate Agreement

Axiogen offers a standard BAA that is designed to satisfy the requirements of 45 C.F.R. §164.504(e) and §164.314(a). Its principal terms include:

TopicAxiogen's standard position
Permitted uses and disclosuresOnly to perform the Services for the customer as set out in the Agreement, for Axiogen's proper management and administration, and as required by law
SafeguardsAdministrative, physical, and technical safeguards that reasonably and appropriately protect the confidentiality, integrity, and availability of electronic PHI, consistent with the Security Rule (45 C.F.R. Part 164, Subpart C)
ReportingReport to the customer any use or disclosure not permitted by the BAA, any Security Incident, and any Breach of Unsecured PHI without unreasonable delay and no later than [10 / 30 — select; must not exceed 60] calendar days after discovery, with the information the customer needs to meet its own notification obligations under 45 C.F.R. §§164.404–164.410
SubcontractorsWritten agreements with any subcontractor that creates, receives, maintains, or transmits PHI, imposing the same restrictions and conditions that apply to Axiogen
Individual rightsMake PHI available for access and amendment, and provide information for an accounting of disclosures, as directed by the customer and within the timeframes the BAA specifies
Books and recordsMake internal practices, books, and records relating to PHI available to the Secretary of Health and Human Services for compliance determination
Term and terminationCustomer may terminate if Axiogen materially breaches the BAA and fails to cure; on termination, PHI is returned or destroyed, or, where infeasible, protections are extended for as long as PHI is retained
PrecedenceThe BAA controls over the Agreement and DPA with respect to PHI

We review customer-paper BAAs on request. Because Axiogen operates a multi-tenant platform with standardized controls, we are generally unable to accept terms that require customer-specific infrastructure or that conflict with the standard positions above, but we will discuss reasonable modifications.


5. Safeguards that support the HIPAA Security Rule

The controls below are part of Axiogen's security program for all customers. They are described in more depth in our Security & Trust Overview and in Annex II of the Data Processing Addendum.

Administrative safeguards

  • Designated security lead [title] responsible for the security program
  • Documented security and privacy policies, reviewed at least annually
  • Risk analysis and risk management performed at least annually and upon significant change
  • Workforce security and privacy training at onboarding and at least annually; sanctions policy for violations
  • Information-access management based on role and least privilege, with periodic access reviews
  • Security incident procedures, a contingency plan (backup, disaster recovery, emergency-mode operation), and periodic evaluation
  • Written agreements with subcontractors and sub-processors

Physical safeguards

  • Hosting in [Cloud Provider] data centers with physical access controls, environmental protections, and independent third-party audits; Axiogen personnel have no physical access to hosting infrastructure
  • Workstation and device controls: managed devices with full-disk encryption, screen lock, and remote wipe
  • Media disposal and re-use procedures aligned with NIST guidance

Technical safeguards

  • Unique user identification; SAML single sign-on with multi-factor authentication; SCIM-based automated provisioning and deprovisioning
  • Role-based and row-level access controls enforcing tenant isolation
  • Encryption of data in transit (TLS 1.3) and at rest (AES-256)
  • Immutable audit log of user and administrative activity, with retention to support customers' accounting-of-disclosures and compliance requirements
  • Integrity controls including checksums, change tracking, and tamper-evident logging
  • Automatic session timeout and emergency-access procedures

6. Breach notification approach

If we discover a Breach of Unsecured PHI, Security Incident, or other impermissible use or disclosure covered by a BAA, we will:

  1. contain and investigate the event immediately;
  2. notify the affected customer within the period specified in the BAA (and in any event within the time needed for the customer to meet its 60-day obligation to notify individuals, HHS, and, where applicable, the media);
  3. provide, as information becomes available, the identification of each individual whose PHI was or is reasonably believed to have been affected, a description of what happened, the types of PHI involved, the steps individuals should take, what we are doing to investigate and mitigate, and contact details;
  4. cooperate with the customer's investigation and notifications; and
  5. conduct a post-incident review and implement corrective actions.

Axiogen does not notify individuals, regulators, or the media on a customer's behalf unless the BAA or the customer directs otherwise.


7. How to request a BAA

  • Existing customers: contact your account manager or email [Legal Contact Email] (e.g., legal@axiogen.ai) with the subject line "BAA request," identifying the Covered Entity or Business Associate that will be party to the BAA and the categories of PHI you expect to upload.
  • Prospective customers: include your BAA requirement in your initial conversation with enterprise@axiogen.ai so that the appropriate terms and Platform configuration are in place before onboarding.
  • Security documentation: our Security Packet, including [the most recent SOC 2 Type II report, if issued] and a HIPAA Security Rule control mapping, is available under NDA — see [Link to request SOC 2 report under NDA].

We aim to acknowledge BAA requests within [2] business days and to return a draft within [5] business days.


8. Related documents

  • Security & Trust Overview — full description of the security program
  • Data Processing Addendum — processor terms and technical and organizational measures
  • Privacy Policy — how we handle personal information, including professional data
  • Terms of Service — acceptable use, including the prohibition on uploading PHI without a BAA
  • Contact

Draft notice. This document is provided for informational purposes and as a high-quality starting draft. It does not constitute legal advice. Axiogen's actual policies and agreements must be reviewed, customized, and approved by qualified legal counsel licensed in the relevant jurisdictions before publication or use.

AXIOGEN

The operating system for aesthetics pharma. One unified ontology. Absolute clarity. Built in California.

IGLIX
PLATFORM
  • Overview
  • Data Assets
  • Product Tour
  • Why Platform
SOLUTIONS
  • Commercial
  • Medical Affairs
  • Operations
  • Corporate
PRODUCT
  • Sales Ops
  • Workflow Zones
  • Directory
COMPANY
  • Manifesto
  • Why Axiogen
  • Security
  • Research
  • Contact
LEGAL
  • Privacy
  • Terms
  • DPA
  • HIPAA
  • Security & Trust
  • Contact
© 2026 AXIOGEN AI · ALL RIGHTS RESERVED · BUILT IN CALIFORNIA
PRACTICE GRAPH · AUG 2026 · SOCIAL CORPUS · MAR 2026 · 15-MIN REFRESH ON ACTIVATION